What is Chardan Capital’s Forecast for CRGX FY2025 Earnings?

CARGO Therapeutics, Inc. (NASDAQ:CRGX) – Research analysts at Chardan Capital issued their FY2025 earnings per share estimates for shares of CARGO Therapeutics in a research report issued to clients and investors on Monday, March 24th. Chardan Capital analyst G. Livshits expects that the company will post earnings per share of ($3.59) for the year. Chardan Capital has a “Neutral” rating on the stock. The consensus estimate for CARGO Therapeutics’ current full-year earnings is ($3.69) per share. Chardan Capital also issued estimates for CARGO Therapeutics’ FY2026 earnings at ($3.58) EPS.

Other analysts also recently issued research reports about the stock. Truist Financial downgraded shares of CARGO Therapeutics from a “buy” rating to a “hold” rating and lowered their target price for the company from $32.00 to $7.00 in a report on Thursday, January 30th. Jefferies Financial Group lowered CARGO Therapeutics from a “buy” rating to a “hold” rating and lowered their price objective for the company from $32.00 to $3.00 in a report on Thursday, January 30th. JPMorgan Chase & Co. downgraded CARGO Therapeutics from an “overweight” rating to an “underweight” rating in a research note on Thursday, January 30th. Piper Sandler downgraded CARGO Therapeutics from an “overweight” rating to a “neutral” rating and decreased their price target for the company from $34.00 to $4.00 in a research note on Thursday, January 30th. Finally, William Blair lowered CARGO Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, January 30th. One investment analyst has rated the stock with a sell rating and six have assigned a hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $15.00.

CARGO Therapeutics Price Performance

NASDAQ:CRGX opened at $4.04 on Thursday. The firm has a market cap of $186.05 million, a price-to-earnings ratio of -0.95 and a beta of 1.65. CARGO Therapeutics has a 1-year low of $3.00 and a 1-year high of $25.45. The firm’s fifty day moving average price is $5.67 and its 200 day moving average price is $13.77.

Institutional Investors Weigh In On CARGO Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of CRGX. Red Tree Management LLC acquired a new position in CARGO Therapeutics during the fourth quarter worth $30,293,000. TRV GP VI LLC purchased a new position in shares of CARGO Therapeutics in the fourth quarter valued at $26,924,000. TRV GP V LLC purchased a new position in shares of CARGO Therapeutics in the fourth quarter valued at $25,051,000. Geode Capital Management LLC raised its stake in shares of CARGO Therapeutics by 80.6% during the 3rd quarter. Geode Capital Management LLC now owns 838,279 shares of the company’s stock worth $15,469,000 after buying an additional 374,018 shares during the last quarter. Finally, Sio Capital Management LLC purchased a new stake in shares of CARGO Therapeutics in the 3rd quarter worth about $3,208,000. Institutional investors and hedge funds own 93.16% of the company’s stock.

CARGO Therapeutics Company Profile

CARGO Therapeutics, Inc, a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.